Note 11 - Business Segment Reporting

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

11. Business Segment Reporting

The Company manages its operations as

one

segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through

one

independent distributor, which is the only customer greater than

10%

of sales. The Company’s revenues by geographic region are as follows (in thousands):

	Three Months Ended March 31,
	2019		2018
Consolidated Revenue:
United States	$	7,060	$	7,295
Brazil		2,642		3,526
Other		120		114
Total Revenue	$	9,822	$	10,935